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Background: Intramyocardial transplantation of CD133+ bone marrow stem cells (BMC) yielded promising results in clinical pilot trials. We now 
performed a double-blinded, randomized, placebo-controlled trial (CARDIO133) to determine its impact on global and regional left ventricular (LV) 
function and heart failure symptoms.
Methods: Sixty patients with chronic ischemic heart failure (LVEF<35%) were randomized to undergo either coronary artery bypass grafting 
(CABG) and injection of CD133+ BMC in the non-transmural, hypokinetic infarct border zone (”treated”), or CABG and placebo injection (“control”). 
Outcome was assessed after 6 months, including cardiac MRI and 2D strain echocardiography.
Results: Mean patient age was 62 (37 - 78) yrs, and 57 patients were male. Preoperative heart function data were comparable in both groups. An 
average of 5.6 x10E6 (2 - 13 x 10E6) CD133+ cells with > 95% purity and viability or placebo were delivered via 20 injections, and 3.2 ± 0.5 bypass 
grafts were implanted. Two patients died early and two late during follow-up. The incidence of adverse events was similar in both groups. Six-minute 
walking distance was 392±135 m in the treatment group and 388±90 m in controls. There was no difference in Minnesota Living with Heart Failure 
score, NYHA or CCS class between groups at follow-up. By cardiac MRI, LVEF rose from 26±5 to 30±5% in treated patients and from from 26±5 to 
31±7% in controls (p=0.287). Similarly, there was no difference in the change of LVEDD (p=0.2), LVESD (0.9), LVEDV (p=0.4) or LVESV (p=0.3). By 
2D strain echocardiography, there was no intergroup difference in longitudinal or radial strain in the area-of-interest. However, cell-treated patients 
showed a better recovery of regional wall motion when the AOI was posterior.
Conclusion: In contrast to the findings of previous pilot trials, intramyocardial injection of CD133+ BMC has no relevant effect on LV function and 
heart failure symptoms. Improvements in regional myocardial function are only detectable in patients with posterior infarction, probably because the 
interventricular septum after anterior infarction is not accessible by transepicardial injection.
